JP4874959B2 - Ｈｉｖインテグラーゼインヒビターとしての二環式ヘテロ環 - Google Patents

Ｈｉｖインテグラーゼインヒビターとしての二環式ヘテロ環 Download PDF

Info

Publication number
JP4874959B2
JP4874959B2 JP2007515142A JP2007515142A JP4874959B2 JP 4874959 B2 JP4874959 B2 JP 4874959B2 JP 2007515142 A JP2007515142 A JP 2007515142A JP 2007515142 A JP2007515142 A JP 2007515142A JP 4874959 B2 JP4874959 B2 JP 4874959B2
Authority
JP
Japan
Prior art keywords
oxo
methyl
oxazine
dimethyl
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2007515142A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008501018A (ja
JP2008501018A5 (https=
Inventor
ビー・ナラシムル・ナイドゥ
ジャック・バンヴィル
フランシス・ボーリュー
ティモシー・ピー・コノリー
マーク・アール・クリスタル
ジョン・ディ・マティスケラ
カール・ウレ
セルジュ・プラモンドン
ロジェ・レミラール
マーガレット・イー・ソレンソン
泰次 植田
マイケル・エイ・ウォーカー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2008501018A publication Critical patent/JP2008501018A/ja
Publication of JP2008501018A5 publication Critical patent/JP2008501018A5/ja
Application granted granted Critical
Publication of JP4874959B2 publication Critical patent/JP4874959B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2007515142A 2004-05-28 2005-05-12 Ｈｉｖインテグラーゼインヒビターとしての二環式ヘテロ環 Expired - Fee Related JP4874959B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US57551304P 2004-05-28 2004-05-28
US60/575,513 2004-05-28
US60337104P 2004-08-20 2004-08-20
US60/603,371 2004-08-20
US11/126,891 US7176196B2 (en) 2004-05-28 2005-05-11 Bicyclic heterocycles as HIV integrase inhibitors
US11/126,891 2005-05-11
PCT/US2005/016473 WO2005118593A1 (en) 2004-05-28 2005-05-12 Bicyclic heterocycles as hiv integrase inhibitors

Publications (3)

Publication Number Publication Date
JP2008501018A JP2008501018A (ja) 2008-01-17
JP2008501018A5 JP2008501018A5 (https=) 2008-06-19
JP4874959B2 true JP4874959B2 (ja) 2012-02-15

Family

ID=35456854

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007515142A Expired - Fee Related JP4874959B2 (ja) 2004-05-28 2005-05-12 Ｈｉｖインテグラーゼインヒビターとしての二環式ヘテロ環

Country Status (26)

Country Link
US (2) US7176196B2 (https=)
EP (1) EP1749011B1 (https=)
JP (1) JP4874959B2 (https=)
KR (1) KR101097623B1 (https=)
AR (1) AR049124A1 (https=)
AT (1) ATE412656T1 (https=)
AU (1) AU2005250356C1 (https=)
BR (1) BRPI0511623A (https=)
CA (1) CA2568356C (https=)
CY (1) CY1110266T1 (https=)
DE (1) DE602005010690D1 (https=)
DK (1) DK1749011T3 (https=)
ES (1) ES2315875T3 (https=)
HR (1) HRP20090005T3 (https=)
IL (1) IL179455A (https=)
MX (1) MXPA06013835A (https=)
NO (1) NO20065879L (https=)
NZ (1) NZ551282A (https=)
PE (1) PE20060242A1 (https=)
PL (1) PL1749011T3 (https=)
PT (1) PT1749011E (https=)
RS (1) RS50700B (https=)
RU (1) RU2381228C2 (https=)
SI (1) SI1749011T1 (https=)
TW (1) TWI366567B (https=)
WO (1) WO2005118593A1 (https=)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115601B2 (en) 2004-05-18 2006-10-03 Bristol-Myers Squibb Company HIV integrase inhibitors
CN101146811B (zh) * 2005-03-31 2012-01-11 P.安杰莱蒂分子生物学研究所 Hiv整合酶抑制剂
US7494984B2 (en) * 2005-08-31 2009-02-24 Bristol-Myers Squibb Company Substituted imidazo[1,2-a]pyrimidines as HIV viral DNA integrase inhibitors
CA2622639C (en) * 2005-10-04 2012-01-03 Istituto Di Recerche Di Biologia Molecolare P. Angeletti S.P.A. Hiv integrase inhibitors
US7902182B2 (en) * 2005-11-16 2011-03-08 Bristol-Myers Squibb Company HIV integrase inhibitors
WO2007064316A1 (en) * 2005-11-30 2007-06-07 Bristol-Myers Squibb Company Bicyclic heterocycles as hiv integrase inhibitors
WO2007064502A1 (en) * 2005-12-01 2007-06-07 Bristol-Myers Squibb Company Forms of n-[(4-fluorophenyl)methyl]-4,6,7,9-tetrahydro-3-hydroxy-9,9-dimethyl-4-oxo-pyrimido[2,1-c][1,4]oxazine-2-carboxamide
US20070129379A1 (en) * 2005-12-01 2007-06-07 Bristol-Myers Squibb Company Hiv integrase inhibitors
US7897593B2 (en) * 2006-05-30 2011-03-01 Bristol-Myers Squibb Company HIV integrase inhibitors
US7893055B2 (en) * 2006-06-28 2011-02-22 Bristol-Myers Squibb Company HIV integrase inhibitors
EP2046328A4 (en) * 2006-07-19 2009-10-28 Univ Georgia Res Found PYRIDINONE DIKETOIC ACIDS: INHIBITORS OF HIV REPLICATION IN COMBINATION THERAPY
US7763630B2 (en) * 2007-06-06 2010-07-27 Bristol-Myers Squibb Company HIV integrase inhibitors
US8129398B2 (en) * 2008-03-19 2012-03-06 Bristol-Myers Squibb Company HIV integrase inhibitors
AU2009228254A1 (en) * 2008-03-27 2009-10-01 Bristol-Myers Squibb Company Crystalline form of N-[[4-fluoro-2- (5-methyl-1H-1,2,4-triazol-1-yl) phenyl]methyl]-4,6,7,9-tetrahydro-3- hydroxy-9,9-dimethyl-4-oxo-pyrimido [2,1-c][1,4]oxazine-2-carboxamide, sodium salt monohydrate
WO2010042392A2 (en) * 2008-10-06 2010-04-15 Merck & Co., Inc. Hiv integrase inhibitors
US8143244B2 (en) * 2009-02-26 2012-03-27 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
WO2011045330A1 (en) 2009-10-13 2011-04-21 Tibotec Pharmaceuticals Macrocyclic integrase inhibitors
US8383639B2 (en) 2009-10-15 2013-02-26 Bristol-Myers Squibb Company HIV integrase inhibitors
WO2011071849A2 (en) 2009-12-07 2011-06-16 University Of Georgia Research Foundation, Inc. Pyridinone hydroxycyclopentyl carboxamides: hiv integrase inhibitors with therapeutic applications
PE20121524A1 (es) 2010-01-27 2012-12-03 Viiv Healthcare Co Combinaciones de compuestos que comprenden inhibidores de la integrasa de vih y otros agentes terapeuticos
RU2567385C2 (ru) 2010-04-02 2015-11-10 ЯНССЕН Ар ЭНД Ди АЙРЛЭНД Макроциклические ингибиторы интегразы
WO2012007500A2 (de) 2010-07-15 2012-01-19 Bayer Cropscience Ag Neue heterocyclische verbindungen als schädlingsbekämpfungsmittel
US8791108B2 (en) 2011-08-18 2014-07-29 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
EP4556010A3 (en) 2011-11-30 2025-07-23 Emory University Jak inhibitors for use in the prevention or treatment of a viral disease caused by a coronaviridae
EP2807149A2 (en) * 2012-01-26 2014-12-03 CRO Consulting Limited Agents for treating neurodegenerative disorders
EP2931730B1 (en) 2012-12-17 2019-08-07 Merck Sharp & Dohme Corp. 4-pyridinonetriazine derivatives as hiv integrase inhibitors
EP2986291B1 (en) 2013-04-16 2020-05-27 Merck Sharp & Dohme Corp. 4-pyridone derivative compounds and uses thereof as hiv integrase inhibitors
AU2014267951A1 (en) 2013-05-17 2015-11-19 Merck Sharp & Dohme Corp. Fused Tricyclic Heterocyclic compounds as HIV integrase inhibitors
US9951079B2 (en) 2013-06-13 2018-04-24 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as HIV integrase inhibitors
MD4794B1 (ro) 2013-09-27 2022-02-28 Merck Sharp & Dohme Corp Derivaţi de chinolizină substituiţi utili ca inhibitori de integrază HIV
WO2016187788A1 (en) 2015-05-25 2016-12-01 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds useful for treating hiv infection
US10548910B2 (en) 2015-11-17 2020-02-04 Merck Sharp & Dohme Corp. Amido-substituted pyridotriazine derivatives useful as HIV integrase inhibitors
WO2017106071A1 (en) 2015-12-15 2017-06-22 Merck Sharp & Dohme Corp. Spirocyclic quinolizine derivatives useful as hiv integrase inhibitors
WO2017113288A1 (en) 2015-12-31 2017-07-06 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as hiv integrase inhibitors
US10934312B2 (en) 2016-12-02 2021-03-02 Merck Sharp & Dohme Corp. Tricyclic heterocycle compounds useful as HIV integrase inhibitors
JOP20190130A1 (ar) 2016-12-02 2019-06-02 Merck Sharp & Dohme مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv)
WO2018140368A1 (en) 2017-01-26 2018-08-02 Merck Sharp & Dohme Corp. Substituted quinolizine derivatives useful as hiv integrase inhibitors
WO2021050555A1 (en) * 2019-09-10 2021-03-18 X-Chem, Inc. Compositions and uses thereof
CN113912622B (zh) * 2020-07-10 2023-12-01 上海纽思克生物科技有限公司 三环嘧啶酮类化合物、其制备方法、其组合物和用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5693641A (en) * 1996-08-16 1997-12-02 Berlex Laboratories Inc. Bicyclic pyrimidine derivatives and their use as anti-coagulants
NZ533057A (en) 2001-10-26 2005-11-25 Angeletti P Ist Richerche Bio N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
EP1441734B1 (en) 2001-10-26 2007-02-28 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Dihydroxypyrimidine carboxamide inhibitors of hiv integrase
EP1539762A2 (en) 2002-06-26 2005-06-15 Bristol-Myers Squibb Company Bicyclic pyrimidinones as coagulation cascade inhibitors
EP1578748B1 (en) 2002-12-27 2010-09-15 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Tetrahydro-4h-pyrido[1,2-a]pyrimidines and related compounds useful as hiv integrase inhibitors
AR046938A1 (es) 2003-12-12 2006-01-04 Merck & Co Inc Procedimiento para preparar hexahidropirimido[1,2-a]azepin-2-carboxilatos y compuetos similares
TW200526635A (en) 2003-12-22 2005-08-16 Shionogi & Co Hydroxypyrimidinone derivative having HIV integrase inhibitory activity
RU2403066C2 (ru) 2004-12-03 2010-11-10 Мерк Шарп Энд Домэ Корп Применение атазанавира для улучшения фармакокинетики лекарственных средств, метаболизируемых ugt1a1
CN101146811B (zh) 2005-03-31 2012-01-11 P.安杰莱蒂分子生物学研究所 Hiv整合酶抑制剂

Also Published As

Publication number Publication date
EP1749011B1 (en) 2008-10-29
WO2005118593A1 (en) 2005-12-15
JP2008501018A (ja) 2008-01-17
ATE412656T1 (de) 2008-11-15
ES2315875T3 (es) 2009-04-01
RS50700B (sr) 2010-06-30
AU2005250356A1 (en) 2005-12-15
KR101097623B1 (ko) 2011-12-22
US7176196B2 (en) 2007-02-13
AR049124A1 (es) 2006-06-28
CA2568356C (en) 2012-07-03
CA2568356A1 (en) 2005-12-15
AU2005250356B2 (en) 2011-03-17
US7511037B2 (en) 2009-03-31
PE20060242A1 (es) 2006-03-31
KR20070039502A (ko) 2007-04-12
SI1749011T1 (sl) 2009-08-31
US20050267105A1 (en) 2005-12-01
RU2381228C2 (ru) 2010-02-10
TWI366567B (en) 2012-06-21
MXPA06013835A (es) 2007-02-02
BRPI0511623A (pt) 2008-03-11
DK1749011T3 (da) 2009-02-16
CY1110266T1 (el) 2015-01-14
PT1749011E (pt) 2008-11-27
DE602005010690D1 (de) 2008-12-11
NZ551282A (en) 2009-05-31
PL1749011T3 (pl) 2009-04-30
TW200600503A (en) 2006-01-01
EP1749011A1 (en) 2007-02-07
US20060276466A1 (en) 2006-12-07
NO20065879L (no) 2007-02-20
HRP20090005T3 (hr) 2009-02-28
IL179455A (en) 2011-10-31
IL179455A0 (en) 2007-05-15
RU2006146970A (ru) 2008-07-10
HK1107343A1 (en) 2008-04-03
AU2005250356C1 (en) 2011-10-06

Similar Documents

Publication Publication Date Title
JP4874959B2 (ja) Ｈｉｖインテグラーゼインヒビターとしての二環式ヘテロ環
EP1948666B1 (en) Hiv integrase inhibitors
US20060199956A1 (en) Bicyclic heterocycles as HIV integrase inhibitors
WO2007143446A1 (en) Spiro-condensed heterotricyclic compounds as hiv integrase inhibitors
WO2008002959A2 (en) Hiv integrase inhibitors
JP2017503786A (ja) Ｎｒｆ２レギュレーター
JP2009515985A (ja) Ｈｉｖインテグラーゼインヒビター
JP2016516692A (ja) ヒト免疫不全ウイルス複製の阻害剤
WO2007059125A2 (en) Hiv integrase inhibitors
WO2007064316A1 (en) Bicyclic heterocycles as hiv integrase inhibitors
WO2007064619A1 (en) Pyrimidine derivatives as hiv integrase inhibitors
US7491819B1 (en) N-[4-Fluorophenyl)methyl]-4,6,7,9-tetrahydro-3-hydroxy-9,9-dimethyl-4-oxo-pyrimido[2,1-c][1,4]oxazine-2-carboxamide as an HIV integrase inhibitor
WO2008154246A1 (en) Hiv integrase inhibitors
CN1989141B (zh) 作为hiv整合酶抑制剂的双环杂环
WO2007058646A1 (en) Hiv integrase inhibitors: cyclic pyrimidinone compounds
HK1107343B (en) Bicyclic heterocycles as hiv integrase inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080501

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080501

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20111115

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20111124

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20141202

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees